Outcome after intracranial hemorrhage under dabigatran and reversal with idarucizumab versus under vitamin-K-antagonists – the RIC-ICH study

BACKGROUND: Intracranial hemorrhage (ICH) is a rare but serious side effect associated with the use of oral anticoagulants, such as dabigatran. The specific reversal agent for dabigatran, idarucizumab, is available for the management of individuals with ICH. The aim of this study was to provide real...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuklik, Nils, Hüsing, Anika, Stang, Andreas, Brinkmann, Marcus, Eschenfelder, Christoph C., Weimar, Christian, Diener, Hans-Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404847/
https://www.ncbi.nlm.nih.gov/pubmed/37554390
http://dx.doi.org/10.3389/fneur.2023.1212495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404847/
https://www.ncbi.nlm.nih.gov/pubmed/37554390
http://dx.doi.org/10.3389/fneur.2023.1212495

Ejemplares similares